Исследование прогресса кардиотоксичности, вызванной ингибиторами иммунных контрольных точек PD-1/PD-L1
Кардиотоксичность (КТ) является серьезным побочным эффектом противоопухолевых препаратов, особенно рецептора смерти 1 (PD-1) или лиганда смерти 1 (PD-L1). Ингибиторы иммунной контрольной точки (ИКТ) привлекли к себе широкое внимание в последние годы. В статье описан прогресс в изучении КТ, вызванной PD-1 и PD-1/PD-L1 ингибиторами ИКТ. Представлен обзор ингибиторов ИКТ PD-1 и PD-1/PD-L1, их проявления КТ, потенциальные механизмы, методы диагностики и лечения.Синьи Ян, Решетов И.В., Полтавская М.Г., Агакина Ю.С., Куликов Т.С.
Ключевые слова
PD-1/PD-L1
ингибиторы иммунных контрольных точек
кардиотоксичность
Список литературы
1. Beyer A.M., Bonini M.G., Moslehi J. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. Am J Physiol Heart Circ Physiol. 2019;317(1):H164–Н1677. doi: 10.1152/ajpheart.00277.2019.
2. Xia L., Liu Y., Wang Y.. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist 2019;24(Suppl. 1):S31–S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
3. Spallarossa P., Meliota G., Brunelli C., et al. Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. Med Res Rev. 2018;38(5):1447–68. doi: 10.1002/med.21478.
4. Inno A., Metro G., Bironzo P., et al. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori. 2017;103(5):405–21. doi: 10.5301/tj.5000625.
5. Wu Y., Lin L., Liu X. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors. Dis Markers. 2020;2020:7291586. doi: 10.1155/2020/7291586.
6. Khunger A., Battel L., Wadhawan A., et al. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. Curr Oncol Rep. 2020;22(7):65. doi: 10.1007/s11912-020-00925-8.
7. Lyon A.R., Yousaf N., Battisti N.M.L., et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet. Oncol. 2018;19(9):447–58. doi: 10.1016/S1470-2045(18)30457-1.
8. Boussiotis V.A. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med 2016;375(18):1767–78. Doi: 10.1056/NEJMra1514296.
9. Varricchi G., Galdiero M.R., Marone G., et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2(4):e000247. doi: 10.1136/esmoopen-2017-000247.
10. Varricchi G., Marone G., Mercurio V., et al. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Curr Med Chem. 2018;25(11):1327–39. doi: 10.2174/0929867324666170407125017.
11. Boutros C., Tarhini A., Routier E., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–86. doi: 10.1038/nrclinonc.2016.58.
12. Spain L., Walls G., Julve M., et al. Neurotoxicity from immunecheckpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann. Oncol. 2017;28(2):377–85. doi: 10.1093/annonc/mdw558.
13. Michot J.M., Bigenwald C., Champiat S., et al. Immune–related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer.2016;54:139–48.
14. Zhang J.C., Chen W.D., Alvarez J.B., et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacol. Sinica. 2018;39(11):1693–98. doi: 10.1038/s41401-018-0062-2.
15. Johnson D.B., Balko J.M., Compton M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55. doi: 10.1056/NEJMoa1609214.
16. Choi J., Lee S.Y. Clinical Characteristics and Treatment of ImmuneRelated Adverse Events of Immune Checkpoint Inhibitors. Immune Netw. 2020;20(1):e9. doi: 10.4110/in.2020.20.e9.
17. Zhang C., Liu Y., Wang H., et al. Real-world Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study. Scientific Reports. 2024;14(5):76829. doi: 10.1038/s41598-024-76829-5.
18. Konala V.M., Adapa S., Aronow W.S. Immune Checkpoint InhibitorsRelated Cardiotoxicity. Am J Ther. 2020;27(6):e591–e598. doi: 10.1097/MJT.0000000000000988.
19. Zhou Y.W., Zhu Y.J., Wang M.N., et al. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. Front Pharmacol. 2019;10:1350. doi: 10.3389/fphar.2019.01350.
20. Baraibar I., Melero I., Ponz-Sarvise M., et al. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Saf. 2019;42(2):281–94. doi: 10.1007/s40264-018-0774-8.
21. Chen D.Y., Huang W.K., Chien-Chia Wu V., et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020;119(10):1461–75. doi: 10.1016/j.jfma.2019.07.025.
22. Palaskas N., Lopez-Mattei J., Durand J.B., et al. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. doi: 10.1161/JAHA.119.013757.
23. Raikhelkar J., Uriel N. Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol. 2019;34(3):303–6. doi: 10.1097/HCO.0000000000000622.
24. Peleg Hasson S., Salwen B., Sivan A., et al. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. Clin Res Cardiol. 2020;110(1):50–60. doi: 10.1007/s00392-020-01648-3.
25. Slawinski G., Wrona A., Dabrowska-Kugacka A., et al. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. Int J Mol Sci. 2020;21(19):7195. doi: 10.3390/ijms21197195.
26. Mahmood S.S., Fradley M.G., Cohen J.V., et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. doi: 10.1016/j.jacc.2018.02.037.
27. Altan M., Toki M.I., Gettinger S.N., et al. Immune Checkpoint Inhibitor-Associated Pericarditis. J Thorac Oncol. 2019;14(6):1102–8. doi: 10.1016/j.jtho.2019.02.026.
28. Trontzas I.P., Vathiotis I.A., Kyriakoulis K.G., et al. Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases. Cancers (Basel). 2023;15(9):2637. doi: 10.3390/cancers15092637.
29. Shalata W., Abu-Salman A., Steckbeck R., et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers (Basel). 2021;13(20):5218. doi: 10.3390/cancers13205218.
30. Sarocchi M., Grossi F., Arboscello E., et al. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. Oncologist. 2018;23(8):936–42. doi: 10.1634/theoncologist.2017-0452.
31. Martin Huertas R., Saavedra Serrano C., Perna C., et al. Cardiac toxicity of immune-checkpoint inhibitors: A clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges. Cancer Manag Res. 2019;11:4541–8. doi: 10.2147/CMAR.S185202.
32. Zlotoff D.A., Hassan M.Z.O., Zafar A., et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9(3):e002007. Doi: 10.1136/jitc-2020-002007.
33. Poto R., Troiani T., Criscuolo G., et al. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol. 2022;13:804597. doi: 10.3389/fimmu.2022.804597.
34. Ganesh S., Zhong P., Zhou X. Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. Front Cardiovasc Med. 2022;9:997660. doi: 10.3389/fcvm.2022.997660.
Об авторах / Для корреспонденции
Автор для связи: Ян Синьи, аспирант кафедры онкологии, реконструктивной хирургии и радиологии, Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет), Москва, Россия; xinyiyang@yandex.ru; ORCID: https://orcid.org/0009-0009-2320-0834
Также по теме
